News

Eveliqure Biotechnologies GmbH announced the initiation of clinical testing for its ShigETEC vaccine candidate, with the dosing of the first subject…

Read more

Proper folding of extremely long chromosomal DNA molecules is crucial for the correct functioning of the cell. Scientists from the Gerlich lab at IMBA…

Read more

The Vienna Covid-19 Detection Initiative (VCDI) is a collaborative, inter-institutional effort to combat the SARS-CoV-2 coronavirus. It draws from…

Read more

Valneva announced the retirement of its Chief Financial Officer, David Lawrence, at the end of 2020.

 

Read more

Read more

The Aligning Science Across Parkinson’s Initiative (ASAP) has awarded a grant to Sascha Martens’ group and scientists from the University of…

Read more

Eveliqure Biotechnologies GmbH announced the award of a US government contract from the National Institute of Allergy and Infectious Diseases (NIAID),…

Read more

CEBINA GmbH announced further positive results in its collaborative COVID-19 drug repurposing project, demonstrating that a common allergy nasal spray…

Read more

A new role for Casein Kinase-1 on RNF43 is identified – Study by Tadasuke Tsukiyama and IMBA – Institute of Molecular Biotechnology of the Austrian…

Read more

Valneva announced a vaccine partnership with the UK government for its inactivated COVID-19 vaccine, VLA2001.

Read more

Read more

Since 1947, the City of Vienna honours residents distinguished in a range of disciplines with the “Preis der Stadt Wien” awards for their life…

Read more

Valneva announced the signing of a new contract, lasting up to three years, with the U.S. government Department of Defense (DoD) for the supply of its…

Read more

Valneva announced the initiation of a pivotal Phase 3 clinical trial for its differentiated, single-shot chikungunya vaccine candidate VLA1553.  The…

Read more